Organization Profile

You just read:

Health Canada issues Notice of Compliance with Conditions (NOC/c) for LibtayoTM (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinoma (CSCC)

News provided by

Sanofi-Aventis Canada Inc.

Apr 11, 2019, 14:43 ET